title: Phase II trial of cisplatin, adriamycin, and etoposide for metastatic endometrial adenocarcinoma.
abstract: Twenty patients with metastatic or recurrent endometrial adenocarcinoma not amenable to surgery or radiation were treated with monthly cisplatin (20 mg/m2 x 3), etoposide (75 mg/m2 x 3), Adriamycin (40 mg/m2) (PAV) and Megace. Patient characteristics were as follows: grade 3 differentiation, 55%; papillary subtype, 15%; prior radiotherapy, 70%; prior chemotherapy, 10%; and prior hormonal therapy, 20%. Hematologic toxicity was significant but acceptable: WBC nadirs, 50%; platelet nadirs, 40%. There was no hematologic mortality. There was a 75% objective response rate and a 55% complete response rate with PAV. The median survival was 15+ months, the 2-year survival was 42%, and the 2-year progression-free survival was 20%. PAV appears to be an active combination with acceptable toxicity in the treatment of metastatic or recurrent endometrial cancer, and we believe that phase III evaluation is indicated.
authors.affiliation: Department of Gynecologic Oncology, Roswell Park Memorial Institute, Buffalo, NY 14263.
authors.forename: M S
authors.initials: MS
authors.lastname: Piver
authors.forename: J
authors.initials: J
authors.lastname: Fanning
authors.forename: T R
authors.initials: TR
authors.lastname: Baker
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015996:Survival Rate; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin